155 related articles for article (PubMed ID: 37036560)
1. Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study.
Borte M; Hanitsch LG; Mahlaoui N; Fasshauer M; Huscher D; Speletas M; Dimou M; Kamieniak M; Hermann C; Pittrow D; Milito C
J Clin Immunol; 2023 Aug; 43(6):1259-1271. PubMed ID: 37036560
[TBL] [Abstract][Full Text] [Related]
2. Facilitated subcutaneous immunoglobulin use in pediatric patients with primary or secondary immunodeficiency diseases.
Baumann U; Fasshauer M; Pausch C; Wittkowski H; Hermann C; Pittrow D; Borte M
Immunotherapy; 2022 Feb; 14(2):135-143. PubMed ID: 34743590
[No Abstract] [Full Text] [Related]
3. Use of recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin in elderly patients.
Paassen PV; Pittrow D; Scheidegger C; Klotsche J; Ellerbroek PM
Immunotherapy; 2020 Feb; 12(2):131-139. PubMed ID: 32066296
[No Abstract] [Full Text] [Related]
4. Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis.
Dimou M; Speletas M; Milito C; Pyzik A; Huscher D; Kamieniak M; Pittrow D; Borte M
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760493
[TBL] [Abstract][Full Text] [Related]
5. Facilitated Subcutaneous Immunoglobulin Replacement Therapy in Clinical Practice: A Two Center, Long-Term Retrospective Observation in Adults With Primary Immunodeficiencies.
Wiesik-Szewczyk E; Sołdacki D; Paczek L; Jahnz-Różyk K
Front Immunol; 2020; 11():981. PubMed ID: 32670265
[TBL] [Abstract][Full Text] [Related]
6. Facilitated subcutaneous immunoglobulin treatment patterns in pediatric patients with primary immunodeficiency diseases.
Mach-Tomalska M; Pituch-Noworolska A; Bień E; Malanowska M; Machura E; Pukas-Bochenek A; Chrobak E; Pac M; Pietrucha B; Drygała S; Kamieniak M; Kasprzak J; Heropolitańska-Pliszka E
Immunotherapy; 2024 Apr; 16(6):391-403. PubMed ID: 38362629
[TBL] [Abstract][Full Text] [Related]
7. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.
Ponsford M; Carne E; Kingdon C; Joyce C; Price C; Williams C; El-Shanawany T; Williams P; Jolles S
Clin Exp Immunol; 2015 Dec; 182(3):302-13. PubMed ID: 26288095
[TBL] [Abstract][Full Text] [Related]
8. Facilitated Subcutaneous Immunoglobulin Treatment Increases the Quality of Life and Decreases the Number of Infections and Hospitalizations in Children with Primary Immunodeficiencies.
Erbaş Açıcı N; Topyildiz E; Aygün A; Geyik M; Edeer Karaca N; Aksu G; Kutukculer N
Int Arch Allergy Immunol; 2024; 185(4):382-391. PubMed ID: 38246144
[TBL] [Abstract][Full Text] [Related]
9. Real-World Experiences With Facilitated Subcutaneous Immunoglobulin Substitution in Patients With Hypogammaglobulinemia, Using a Three-Step Ramp-Up Schedule.
Hustad NB; Degerud HM; Hjelmerud I; Fraz MSA; Nordøy I; Trøseid M; Fevang B; Aukrust P; Jørgensen SF
Front Immunol; 2021; 12():670547. PubMed ID: 34012453
[TBL] [Abstract][Full Text] [Related]
10. A Phase 1 Open-Label Study to Assess the Tolerability, Safety, and Immunogenicity of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 20% in Healthy Adults.
Nagy A; Duff K; Bauer A; Okonneh F; Rondon JC; Yel L; Li Z
J Clin Immunol; 2023 Dec; 44(1):28. PubMed ID: 38129731
[TBL] [Abstract][Full Text] [Related]
11. Efficacy-safety of Facilitated Subcutaneous Immunoglobulin in Immunodeficiency Due to Hematological Malignancies. A Single-Center Retrospective Analysis.
Dimou M; Iliakis T; Maltezas D; Bitsani A; Kalyva S; Koudouna A; Kotsanti S; Petsa P; Papaioannou P; Kyrtsonis MC; Panayiotidis P
Anticancer Res; 2018 Jul; 38(7):4187-4191. PubMed ID: 29970548
[TBL] [Abstract][Full Text] [Related]
12. Infusion parameters of 20% subcutaneous immunoglobulin for primary immunodeficiency diseases among patient support program participants.
Meckley LM; Wu Y; Tzivelekis S; Gandhi V; Gladiator A
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):568-574.e1. PubMed ID: 34224864
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of immunoglobulin G after intravenous, subcutaneous, or hyaluronidase-facilitated subcutaneous administration in immunoglobulin-naive patients with primary immunodeficiencies.
Li Z; Follman K; Freshwater E; Engler F; Yel L
Int Immunopharmacol; 2024 Feb; 128():111447. PubMed ID: 38185032
[TBL] [Abstract][Full Text] [Related]
14. Real-World Use, Safety, and Patient Experience of 20% Subcutaneous Immunoglobulin for Primary Immunodeficiency Diseases.
Fasshauer M; Borte M; Bitzenhofer M; Pausch C; Pittrow D; Park M; Gladiator A; Jandus P
Adv Ther; 2023 Dec; 40(12):5168-5187. PubMed ID: 37751025
[TBL] [Abstract][Full Text] [Related]
15. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry.
Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S
J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437
[TBL] [Abstract][Full Text] [Related]
16. Facilitated subcutaneous immunoglobulin administration (fSCIg): a new treatment option for patients with secondary immune deficiencies.
Blau IW; Conlon N; Petermann R; Nikolov N; Plesner T
Expert Rev Clin Immunol; 2016 Jul; 12(7):705-11. PubMed ID: 27156362
[TBL] [Abstract][Full Text] [Related]
17. Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.
Bienvenu B; Cozon G; Mataix Y; Lachaud D; Alix A; Hoarau C; Antier D; Hachulla E; Brice S; Viallard JF; Tamisier S; Fauchais AL; Renon-Carron F; Clerson P; Fardini Y; Crave JC; Miossec P
J Clin Immunol; 2018 May; 38(4):503-512. PubMed ID: 29855752
[TBL] [Abstract][Full Text] [Related]
18. Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study.
Keith PK; Cowan J; Kanani A; Kim H; Lacuesta G; Lee JK; Chen J; Park M; Gladiator A
Allergy Asthma Clin Immunol; 2022 Aug; 18(1):70. PubMed ID: 35934726
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy, safety, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (Ig) (fSCIG; HyQvia(
Angelotti F; Capecchi R; Giannini D; Mazzarella O; Rocchi V; Migliorini P
Clin Exp Med; 2020 Aug; 20(3):387-392. PubMed ID: 32385734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
